使用负载人白细胞抗原A*0201限制性肽的树突状细胞对巨细胞病毒特异性CD4+和CD8+ T淋巴细胞进行选择性体外扩增。

Selective ex vivo expansion of cytomegalovirus-specific CD4+ and CD8+ T lymphocytes using dendritic cells pulsed with a human leucocyte antigen A*0201-restricted peptide.

作者信息

Vannucchi A M, Glinz S, Bosi A, Caporale R, Rossi-Ferrini P

机构信息

The Bone Marrow Transplant Unit, Division of Haematology, Azienda Ospedaliera Careggi, University of Florence, Florence, Italy.

出版信息

Br J Haematol. 2001 May;113(2):479-82. doi: 10.1046/j.1365-2141.2001.02777.x.

DOI:10.1046/j.1365-2141.2001.02777.x

PMID:11380419

Abstract

Adoptive transfer of ex vivo-generated cytomegalovirus (CMV)-specific T lymphocytes may be effective in preventing CMV disease in allogeneic haematopoietic stem cell transplantation (HSCT) recipients. We developed a procedure for expansion of CMV-specific T lymphocytes based on the antigen-presenting function of donor dendritic cells (DCs), pulsed with a human leucocyte antigen A*0201-restricted pp65 nonamer peptide. CMV-specific T lymphocytes were identified following induction of interferon gamma (IFN-gamma) secretion prompted by peptide exposure. Both CD8+ and CD4+ CMV-specific T lymphocytes were selectively produced in these cultures and showed CMV-restricted cytotoxicity. The simultaneous and selective expansion of CD4+ and CD8+ CMV-specific lymphocytes might be instrumental for more efficient in vivo function of infused CMV-specific lymphocytes.

摘要

过继转移体外产生的巨细胞病毒（CMV）特异性T淋巴细胞可能对预防异基因造血干细胞移植（HSCT）受者的CMV疾病有效。我们基于供体树突状细胞（DC）的抗原呈递功能，开发了一种扩增CMV特异性T淋巴细胞的方法，用人类白细胞抗原A*0201限制性pp65九聚体肽进行脉冲处理。在肽暴露引发干扰素γ（IFN-γ）分泌后，鉴定出CMV特异性T淋巴细胞。在这些培养物中选择性产生了CD8⁺和CD4⁺CMV特异性T淋巴细胞，并表现出CMV限制性细胞毒性。CD4⁺和CD8⁺CMV特异性淋巴细胞的同时选择性扩增可能有助于提高输注的CMV特异性淋巴细胞在体内的功能效率。